Tag: Posaconazole

Invasive aspergillosis is a major cause of death in immunocompromised patients [1.2.4]. As a broad-spectrum triazole antifungal, a key question for clinicians is: **Does posaconazole cover Aspergillus?** Yes, posaconazole demonstrates potent activity against Aspergillus species and is used for both prevention and treatment [1.2.1, 1.2.3].

Clinical studies and case reports confirm that the antifungal posaconazole is associated with an increased risk of hypokalemia, or low blood potassium levels. This occurs due to its inhibitory effects on specific adrenal steroid-producing enzymes, leading to a condition known as pseudohyperaldosteronism. Awareness and monitoring are critical for managing this potential adverse effect during treatment.

Clinical trials for posaconazole have shown that diarrhea is a very common side effect, occurring in some patients receiving the oral suspension at an incidence of up to 42%. This gastrointestinal reaction is a frequently reported adverse event, making it a key consideration for patients prescribed this antifungal medication.

Recent data estimates that invasive fungal infections affect millions worldwide, with approximately 250,000 cases of invasive aspergillosis and 700,000 cases of invasive candidiasis annually. This article explores what posaconazole is used for in combating these serious infections.